Eyemaxx Real Estate AG

  • WKN: A0V9L9
  • ISIN: DE000A0V9L94
  • Land: Deutschland

Nachricht vom 14.10.2019 | 17:16

Eyemaxx Real Estate AG : Eyemaxx: Johann Kowar increases stake to more than 15 percent

DGAP-News: Eyemaxx Real Estate AG / Key word(s): Miscellaneous

14.10.2019 / 17:16
The issuer is solely responsible for the content of this announcement.


CORPORATE NEWS

Eyemaxx: Johann Kowar increases stake to more than 15 percent

Aschaffenburg, 14 October 2019 - Eyemaxx Real Estate AG (General Standard; ISIN: DE000A0V9L94; "Eyemaxx") welcomes the increase in the stake of the renowned real estate investor Johann Kowar to now more than 15 percent. The former CEO of the real estate company conwert has already held a shareholding in Eyemaxx for several years and has now increased its stake further. Next to Eyemaxx CEO Dr. Michael Müller, who currently holds about 31.50 percent of Eyemaxx, Kowar continues to be the second largest shareholder of the company.

Johann Kowar explains the increase in his stake: "Eyemaxx has had a very good development and excellent prospects - with a focus on high-growth real estate segments in Germany and Austria and the combination of project development and the management of portfolio properties. Consequently, I have used the currently favourable level of the share price to further increase my shareholding in the company. My investment in Eyemaxx is a long term one, and I am looking forward towards accompanying the company on its further growth path as a shareholder and benefit from rising share prices."

About Eyemaxx Real Estate AG

Eyemaxx Real Estate AG is a real estate company with a long-standing successful track record, focussing on residential properties in Germany and Austria. In the company's recent past its corporate strategy has also included hotels and serviced apartments as well as developing urban districts in Germany.

Eyemaxx' business activities take a dual-pronged approach. These include high-margin projects and also the continued expansion of its stocks of let commercial properties, which generate ongoing rental income and thus constant cash flows. In so doing, Eyemaxx uses the expertise offered by its experienced management team together with a strong team of real estate professionals, and also a well-established and broad network which opens up additional access to attractive properties and projects. As a result, the current project pipeline has been grown to a total of around EUR 855 million.

Shares of Eyemaxx Real Estate AG are listed in the General Standard of the Frankfurt Stock Exchange and in the direct market plus on the Vienna Stock Exchange. The company has also issued several bonds, which are likewise listed on the stock exchange.

You can find more information at www.eyemaxx.com

Contact

Investor Relations / Financial Press
Axel Mühlhaus, Peggy Kropmanns
edicto GmbH
Telephone: +49 69 905505-52
E-Mail: eyemaxx@edicto.de



14.10.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Anleihe im Fokus

Deutsche Rohstoff
"Anleihe - Jetzt zeichnen!"

- Emissionsvolumen: bis zu 100 Mio. EUR
- Zeichnungsfrist: 11.11. bis 04.12.2019
- ISIN: DE000A2YN3Q8 / WKN: A2YN3Q
- Börsenesegment: Börse Frankfurt, Open Market (Quotation Board)
- Stückelung / Emissionspreis: 1.000 EUR/ 100%
- Zinssatz (Kupon): 5,25 %
- Laufzeit: 5 Jahre
- Fälligkeit: 5 Jahre / 6.12.2024 (vorbehaltliche vorzeitige Rückzahlung gemäß Anleihebedingungen)
- Zinszahlung: Angebot an Inhaber der 5,625 % Schuldverschreibung 2016/2021 (WKN A2AA05, ISIN DE000A2AA055) diese in die neue Anleihe zu tauschen
- Umtauschfrist: 11.11.2019 – 29.11.2019 (18.00 Uhr)

GBC-Fokusbox

Expedeon AG mit attraktiver Produktpipeline

Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.

News im Fokus

Henkel AG & Co. KGaA: Henkel bestätigt Ausblick für das Geschäftsjahr 2019

14. November 2019, 07:30

Aktueller Webcast

EQS Group AG

Conference Call zu den Neunmonatszahlen 2019

15. November 2019

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

13. November 2019